Monoclonal Antibodies Reactive with Breast Cancer, Mammary Mucins and Synthetic Peptides

1991 ◽  
pp. 45-54 ◽  
Author(s):  
Pei-xiang Xing ◽  
Ian F. C. McKenzie
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Synthetic Peptides

Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer

2020 ◽  
Vol 21 (11) ◽  
pp. 1097-1102
Author(s):  
Drashti Desai ◽  
Pravin Shende
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Diagnosis And Treatment ◽  
Detection Methods ◽  
Active Immunotherapy ◽  
Immune Checkpoints ◽  
Proliferation Index ◽  
Protein Fusion ◽  
Ki 67 ◽  
Cost Efficient

: Immunotherapy emerges as a treatment strategy for breast cancer marker, diagnosis and treatment. In this review, monoclonal antibodies (mAbs)-based passive and peptide vaccines as active immunotherapy approaches like activation of B-cells and T-cells are studied. Passive immunotherapy is mAbs-based therapy effective against tumor cells, which acts by targeting HER2, IGF 1R, VEGF, BCSC and immune checkpoints. Neuropeptide Y (NPY) and GPCR are the areas of interest to target BC metastases for on-targeting therapeutic action. Neuropeptide S (NPS) or NPS receptor 1, acts as a biomarker for Neuroendocrine tumors (NET), mostly characterized by synaptophysin and chromogranin-A expression or Ki-67 proliferation index. The protein fusion technologies arise as a promising avenue in plant expression systems for increased recombinant Ab accumulation and cost-efficient purification. Recently, mAbs-based immunotherapy effectiveness is appreciated as a novel therapeutic combination of chemotherapy and immunotherapy to reduce the side effects and improve therapeutic responsiveness. Synthetic drug resistance will be overcome by mAbs-based therapy through several clinical trials and detection methods need to be optimized for accuracy and precision. Pharmacokinetic attributes need to be accessed for preferred receptor-agonist activity without ligand accumulation.

Production and characterization of monoclonal antibodies to anti-human chorionic somatomammotropin by immunization with two free synthetic peptides

1985 ◽  
Vol 22 (11) ◽  
pp. 1237-1241 ◽  
Author(s):  
G. Antoni ◽  
M. Mariani ◽  
R. Presentini ◽  
M. Lafata ◽  
P. Neri ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Synthetic Peptides ◽  
Chorionic Somatomammotropin

In Vivo Studies of Radiolabeled Monoclonal Antibodies Mc5 and KC4 in Human Breast Cancer

1989 ◽  
pp. 237-248
Author(s):  
Paul A. Bunn ◽  
David G. Dienhart ◽  
Raymond F. Schmelter ◽  
James L. Lear ◽  
Gary Miller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Human Breast Cancer ◽  
In Vivo Studies ◽  
Human Breast

New monoclonal antibodies as probes for human cardiac troponin I: Epitopic analysis with synthetic peptides

1992 ◽  
Vol 29 (2) ◽  
pp. 271-278 ◽  
Author(s):  
Catherine Larue ◽  
Hélène Defacque-Lacquement ◽  
Charles Calzolari ◽  
Dung Le Nguyen ◽  
Bernard Pau
Keyword(s):  
Monoclonal Antibodies ◽  
Cardiac Troponin ◽  
Synthetic Peptides ◽  
Troponin I ◽  
Cardiac Troponin I

Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study.

1991 ◽  
Vol 9 (7) ◽  
pp. 1113-1123 ◽  
Author(s):  
D F Hayes ◽  
R Mesa-Tejada ◽  
L D Papsidero ◽  
G A Croghan ◽  
A H Korzun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Weight ◽  
Monoclonal Antibodies ◽  
High Molecular Weight ◽  
Statistical Significance ◽  
Disease Free Survival ◽  
Immunoperoxidase Staining ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Axillary Lymph Node Metastases

Three monoclonal antibodies (MAbs) (DF3, F36/22, CU18) were used to monitor expression of distinct epitopes present within a family of mucin-like, breast carcinoma-associated molecules. Primary tumor specimens from more than 190 stage II breast cancer patients were evaluated for expression of the high molecular weight antigens. With a median follow-up of 6 years, patients whose tumors exhibited high immunoperoxidase staining scores (greater than 50% positive cells) with MAb DF3 had a superior disease-free survival ([DFS] 56% +/- 6% v 37% +/- 5% at 6 years; P = .0088) and overall survival ([OS] 72% +/- 5% v 59% +/- 5% at 6 years; P = .025). Staining scores with the other two antibodies did not correlate with improved prognosis. For MAbs DF3 and CU18, patients whose tumors exhibited predominantly apical cellular reactivity patterns had improved DFS, although differences reached conventional levels of statistical significance only with MAb CU18. In multivariate analyses, the prognostic value of MAb DF3 staining was independent of other identified prognostic factors. Furthermore, the concordance between primary and axillary lymph node metastases staining with each MAb was 73%, 80%, and 85% for MAbs DF3, F36/22, and CU18, respectively. These results suggest that staining with MAb DF3 identifies a group of node-positive women with a relatively favorable prognosis. Expression of the DF3 mucin-like glycoprotein is related to better differentiation, and staining with MAb DF3 provides an accurate and objective estimate of clinical outcome independent of histopathologic evaluation.

Characterization of Murine Monoclonal Antibodies to HIV-1 Induced by Synthetic Peptides

1988 ◽  
Vol 4 (5) ◽  
pp. 331-342 ◽  
Author(s):  
PAUL J. DURDA ◽  
BARBARA LEECE ◽  
ANNA JENOSKI ◽  
HARVEY RABIN ◽  
AMANDA FISHER ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Synthetic Peptides ◽  
Murine Monoclonal Antibodies ◽  
Hiv 1

Heterogeneity vs. Asynchrony of Receptor Expression in Breast Cancer as Determined by Monoclonal Antibodies

1987 ◽  
pp. 145-156 ◽  
Author(s):  
L. B. Kinsel ◽  
J. L. Flowers ◽  
J. Konrath ◽  
G. S. Leight ◽  
G. L. Greene ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Receptor Expression
Sign in / Sign up

Export Citation Format

Share Document